Federal Register / Vol. 85, No. 226 / Monday, November 23, 2020 / Notices 74739

Despite the widespread availability of has a broad focus on the entire vaccine DEPARTMENT OF HEALTH AND effective vaccines, vaccine-preventable enterprise and is not focused HUMAN SERVICES diseases (VPDs) remain a significant specifically on any one vaccine or the public health challenge. In particular, pandemic response. HHS, through National Institutes of Health rates of non-medical exemptions for OIDP, seeks input regarding the draft of 4 National Institute of Mental Health; childhood vaccines are increasing, and the Vaccine Plan from subject matter Notice of Closed Meeting there have been recent measles experts and nonfederal partners and 5 outbreaks in the U.S. and globally, due stakeholders such as health care Pursuant to section 10(d) of the to growing vaccine hesitancy and providers, national professional Federal Advisory Committee Act, as coverage levels below the threshold organizations, health departments, amended, notice is hereby given of the needed for herd immunity. With an school administrators, community- following meeting. estimated cost of $20,000 per case of The meeting will be closed to the 6 based and faith-based organizations, measles to the public sector in 2016, public in accordance with the the economic consequences of this and manufacturers, researchers, advocates, and persons affected by VPDs. provisions set forth in sections other VPDs, as well as the health 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., consequences, are significant. The following are the Vaccine Plan’s as amended. The grant applications and Furthermore, few adults in any age vision and goals. Vision: United States the discussions could disclose group are fully vaccinated as will be a place where vaccine- confidential trade secrets or commercial recommended by the Advisory preventable diseases are eliminated 2 property such as patentable material, Committee on Immunization Practices. through safe and effective vaccination and personal information concerning Large disparities in vaccine coverage by over the lifespan. Goals: individuals associated with the grant race/ethnicity persist, with African 1. Foster innovation in vaccine applications, the disclosure of which Americans, Hispanics, and Asian would constitute a clearly unwarranted Americans lagging behind whites in development and related technologies. invasion of personal privacy. nearly all vaccination coverage rates.7 2. Maintain the highest possible levels VPDs such as pertussis and hepatitis B of vaccine safety. Name of Committee: National Institute of Mental Health Special Emphasis Panel; continue to take a heavy toll on public 3. Increase knowledge of and health,8 with 18,975 cases of pertussis Mental Health Services Research Special confidence in routinely recommended. Emphasis Panel. and 3,409 (22,000 estimated) cases of 4. Increase access to and use of all Date: December 17, 2020. hepatitis B infections reported in the Time: 2:00 p.m. to 4:00 p.m. 910 routinely recommended vaccines. United States in 2017. In light of Agenda: To review and evaluate grant these challenges, strengthening the 5. Protect the health of the American applications. vaccine and immunization enterprise is public by supporting global Place: National Institutes of Health, a priority for HHS. immunization efforts. Neuroscience Center, 6001 Executive To respond to the public health Boulevard, Rockville, MD 20852 (Telephone challenges of VPDs, OIDP in Information Needs Conference Call). collaboration with other federal partners Contact Person: Nicholas Gaiano, Ph.D., is leading the development of the The draft Vaccine Plan may be Review Branch Chief, Division of Extramural Vaccines National Strategic Plan reviewed at www.hhs.gov/oidp. Activities, National Institute of Mental Health, NIH, Neuroscience Center/Room (Vaccine Plan). This updated plan will OIDP seeks to obtain feedback from 6150/MSC 9606, 6001 Executive Boulevard, recommend vaccine strategies across the external stakeholders on the following: Bethesda, MD 20892–9606, 301–443–2742, lifespan and guide priority actions for 1. Do the draft Vaccine Plan’s goals, [email protected]. the period 2021–2025. While COVID–19 objectives, and strategies appropriately (Catalogue of Federal Domestic Assistance and coronavirus vaccine development address the vaccine landscape? Program No. 93.242, Mental Health Research are currently changing the landscape of Grants, National Institutes of Health, HHS) the vaccine enterprise, the Vaccine Plan 2. Are there any critical gaps in the Vaccine Plan’s goals, objectives, and Dated: November 17, 2020. Patricia B. Hansberger, Advisory Committee: Standards for adult strategies? If so, please specify the gaps. immunization practice. Public Health Rep. Supervisory Program Analyst, Office of 2014;129:115–23. 3. Do any of the Vaccine Plan’s goals, Federal Advisory Committee Policy. 4 Omer, S. et al. Nonmedical exemptions to objectives and strategies cause concern? [FR Doc. 2020–25749 Filed 11–20–20; 8:45 am] school immunization requirements: Secular trends If so, please specify the goal, objective BILLING CODE 4140–01–P and association of state policies with pertussis or strategy, and describe the concern incidence. JAMA. 2006;296(14):1757–1763. regarding it. 5 https://www.cdc.gov/measles/cases- outbreaks.html. Please be succinct and limit your DEPARTMENT OF HEALTH AND 6 Lo NC, Hotez P.J. Public Health and Economic comments to a maximum of seven HUMAN SERVICES Consequences of Vaccine Hesitancy for Measles in pages. the United States. JAMA Pediatr. 2017;171(9):887– National Institutes of Health 892. doi:10.1001/jamapediatrics.2017.1695. Authority: 42 U.S.C. Section 300aa–3. 7 Lu P.J. et al. Racial and Ethnic Disparities in National Institute on Drug Abuse; Vaccination Coverage Among Adult Populations in Dated: November 17, 2020. Notice of Closed Meeting the U.S. Am J. Prev Med. 2015;49(6 Suppl 4):S412– B. Kaye Hayes, S425. doi:10.1016/j.amepre.2015.03.005. 8 https://www.cdc.gov/vaccines/pubs/pinkbook/ Acting Director, Office of Infectious Disease Pursuant to section 10(d) of the downloads/appendices/e/reported-cases.pdf. and HIV/AIDS Policy. Federal Advisory Committee Act, as 9 https://www.chop.edu/centers-programs/ [FR Doc. 2020–25842 Filed 11–20–20; 8:45 am] amended, notice is hereby given of the vaccine-education-center/global-immunization/ BILLING CODE 4150–43–P following meeting. diseases-and-vaccines-world-view. The meeting will be closed to the 10 Schillie et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of public in accordance with the the Advisory Committee on Immunization provisions set forth in sections Practices. MMWR. 2018;67(1):1–31. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

VerDate Sep<11>2014 17:07 Nov 20, 2020 Jkt 253001 PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 E:\FR\FM\23NON1.SGM 23NON1 74740 Federal Register / Vol. 85, No. 226 / Monday, November 23, 2020 / Notices

as amended. The contract proposals and would constitute a clearly unwarranted Agenda: To review and evaluate contract the discussions could disclose invasion of personal privacy. proposals. Place: National Institute of Allergy and confidential trade secrets or commercial Name of Committee: National Institute of property such as patentable material, Infectious Diseases, National Institutes of Allergy and Infectious Diseases Special Health, 5601 Fishers Lane, Room 3G31, and personal information concerning Emphasis Panel; Preclinical and Rockville, MD 20892 (Virtual Meeting). individuals associated with the contract Translational Vaccine Development Support Contact Person: Cynthia L. De La Fuente, proposals, the disclosure of which for HIV and Other Candidate Agents (PTVDS) Ph.D., Scientific Review Officer, Scientific would constitute a clearly unwarranted (N01), Task Areas C and D. Review Program, Division of Extramural invasion of personal privacy. Date: December 17, 2020. Activities, National Institute of Allergy and Time: 10:00 a.m. to 6:00 p.m. Infectious Diseases, National Institutes of Name of Committee: National Institute on Agenda: To review and evaluate contract Health, 5601 Fishers Lane, Room 3G31, Drug Abuse Special Emphasis Panel; DEA- proposals. Rockville, MD 20852, 240–669–2740, Compliant Drug Detection and Deactivation Place: National Institute of Allergy and [email protected]. Technology to Deter Opioid Theft in Infectious Diseases, National Institutes of (Catalogue of Federal Domestic Assistance Hospitals for Next Generation Controlled Health, 5601 Fishers Lane, Room 3G31, Substance Diversion Prevention Program Program Nos. 93.855, Allergy, Immunology, Rockville, MD 20892 (Virtual Meeting). and Transplantation Research; 93.856, (CSDPP) Contact Person: Cynthia L. De La Fuente, Date: December 15, 2020. Microbiology and Infectious Diseases Ph.D., Scientific Review Officer, Scientific Research, National Institutes of Health, HHS) Time: 3:00 p.m. to 5:00 p.m. Review Program, Division of Extramural Agenda: To review and evaluate contract Activities, National Institute of Allergy and Dated: November 17, 2020. proposals. Infectious Diseases, National Institutes of Tyeshia M. Roberson, Place: National Institutes of Health, Health, 5601 Fishers Lane, Room 3G31, Program Analyst, Office of Federal Advisory National Institute on Drug Abuse, 301 North Rockville, MD 20852, 240–669–2740, Committee Policy. Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). [email protected]. [FR Doc. 2020–25799 Filed 11–20–20; 8:45 am] Contact Person: Soyoun Cho, Ph.D., (Catalogue of Federal Domestic Assistance BILLING CODE 4140–01–P Scientific Review Officer, Scientific Review Program Nos. 93.855, Allergy, Immunology, Branch, Division of Extramural Research, and Transplantation Research; 93.856, National Institute on Drug Abuse, NIH, 301 Microbiology and Infectious Diseases DEPARTMENT OF HEALTH AND North Stonestreet Avenue, MSC 6021, Research, National Institutes of Health, HHS) HUMAN SERVICES Bethesda, MD 20892, (301) 594–9460, Dated: November 17, 2020. [email protected]. Tyeshia M. Roberson, National Institutes of Health (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Program Analyst, Office of Federal Advisory National Institute of Allergy and Development Award for Clinicians, Scientist Committee Policy. Infectious Diseases; Notice of Closed Development Awards, and Research Scientist [FR Doc. 2020–25798 Filed 11–20–20; 8:45 am] Meeting Awards; 93.278, Drug Abuse National BILLING CODE 4140–01–P Research Service Awards for Research Pursuant to section 10(d) of the Training; 93.279, Drug Abuse and Addiction Federal Advisory Committee Act, as Research Programs, National Institutes of DEPARTMENT OF HEALTH AND amended, notice is hereby given of the Health, HHS) HUMAN SERVICES following meeting. Dated: November 17, 2020. The meeting will be closed to the Tyeshia M. Roberson, National Institutes of Health public in accordance with the Program Analyst, Office of Federal Advisory provisions set forth in sections Committee Policy. National Institute of Allergy and 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Infectious Diseases; Notice of Closed [FR Doc. 2020–25800 Filed 11–20–20; 8:45 am] as amended. The grant applications and Meeting BILLING CODE 4140–01–P the discussions could disclose Pursuant to section 10(d) of the confidential trade secrets or commercial Federal Advisory Committee Act, as property such as patentable material, DEPARTMENT OF HEALTH AND amended, notice is hereby given of the and personal information concerning HUMAN SERVICES following meeting. individuals associated with the grant applications, the disclosure of which National Institutes of Health The meeting will be closed to the public in accordance with the would constitute a clearly unwarranted invasion of personal privacy. National Institute of Allergy and provisions set forth in sections Infectious Diseases; Notice of Closed 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Name of Committee: National Institute of Meeting as amended. The contract proposals and Allergy and Infectious Diseases Special the discussions could disclose Emphasis Panel NIAID Investigator Initiated Pursuant to section 10(d) of the Program Project Applications (P01 Clinical confidential trade secrets or commercial Trial Not Allowed). Federal Advisory Committee Act, as property such as patentable material, amended, notice is hereby given of the Date: December 16, 2020. and personal information concerning Time: 12:00 p.m. to 4:00 p.m. following meeting. individuals associated with the contract Agenda: To review and evaluate grant The meeting will be closed to the proposals, the disclosure of which applications. public in accordance with the would constitute a clearly unwarranted Place: National Institute of Allergy and provisions set forth in sections invasion of personal privacy. Infectious Diseases, National Institutes of 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Health, 5601 Fishers Lane, Room 3G60, as amended. The contract proposals and Name of Committee: National Institute of Rockville, MD 20892 (Virtual Meeting). the discussions could disclose Allergy and Infectious Diseases Special Contact Person: Gregory P. Jarosik, Ph.D. Emphasis Panel; Preclinical and confidential trade secrets or commercial Scientific Review Program, Division of Translational Vaccine Development Support Extramural Activities, National Institute of property such as patentable material, for HIV and Other Candidate Agents Allergy and Infectious Diseases, National and personal information concerning (PTVDS), Task Areas A and B. Institutes of Health, 5601 Fishers Lane, Room individuals associated with the contract Date: December 14, 2020. 3G60, Rockville, MD 20852, (240) 669–5080, proposals, the disclosure of which Time: 10:00 a.m. to 6:00 p.m. [email protected].

VerDate Sep<11>2014 17:07 Nov 20, 2020 Jkt 253001 PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 E:\FR\FM\23NON1.SGM 23NON1